All News | RheumNow

All News

ChatGPT,computer,learning

ICYMI: ChatGPT - A Boon or Threat to Scientific Publication?

Save

d Jack Cush, MD

Jul 07, 2023

ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more. While this AI driven platform has the untold potential in generating written content, there is considerable concern in assuring that human-generated content of research, education and publishing has veracity.

Read Article

ICYMI: LAVLI - A New Autoinflammatory Disorder

Save

d Jack Cush, MD

Jul 06, 2023

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic inflammation, by altering microvascular permeability and neutrophil recruitment, while at the same time promoting hepatic fibrosis.

Read Article

computer screen safety

ICYMI: Drug Safety Differences with New Novel Therapies in RA

Save

d Jack Cush, MD

Jul 06, 2023

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Read Article

RT @Yuz6Yusof : #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favored DAZ Group. Phase 3 RCTs are underway

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2023

Long-Term Efficacy and Safety of a JAKi in RA How might long-term efficacy and safety data from a study of a JAKi in TNFi-IR patients with RA influence clinical decision making? Watch Dr. Stan Cohen discuss. Sponsored by AbbVie US Medical Affairs https://t.co/mvVtlMJTc2 https://t.co/YJX3nymDuU

Links:

https://bit.ly/3NAhQaE

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2023

RT @Yuz6Yusof : #EULAR2023 #POS0116 How does Voclosporin fare in #lupus pts w/heavy proteinuria (=>2g/day)? Pooled Analyses from Phase 2&3 RCTs showed consistent improvement in renal response regardless of demographics or clinical characteristics. An option this resistant group

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2023

RT @drdavidliew : Tapering pred in RA - this just rings true from everyday clinic life. Some patients just seem to hit a wall at PNL 2.5. Sometimes it’s GC withdrawal arthralgias/tertiary adrenal insufficiency, but often it’s genuine inflammation. I still wonder why? POS0050

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2023

RT @synovialjoints : • Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH) • Bone pain, xanthelasma, hairy kidney • Differential diagnoses of LCH • BRAF mutation associated with cardiac and neurological phenotype of ECD Haroche J, Papo M

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2023

#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2023

RT @AurelieRheumo : The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups #EULAR23 POS0033

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2023

RT @bella_mehta : Obesity in #AOSD – predicted the development of a chronic disease course and biologic DMARD failure, 139 pts with AOSD- 19% Obese (BMI>30) observational study. abst#AB1503 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2023

RT @drdavidliew : Men trying to conceive were prev told to avoid MTX. Another myth busted Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues! OP0224 #EULAR2023 https://t.co/i4WGmoWOwU)

Links:

https://bit.ly/3PGL625

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2023

RT @Yuz6Yusof : #EULAR2023 #POS1075 Which biologics have the lowest retention rate in Elderly patients (=>65 yrs) in Rheumatoid Arthritis? Data from Italian registry showed 1/3 discontinued biologics at 2 yrs. IL6-i: lowest persistence; Abatacept: highest

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2023

RT @Janetbirdope : #ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2023

RT @Janetbirdope : A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2023

RT @Yuz6Yusof : #EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few year

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2023

RT @Janetbirdope : Cool way to get peg uricase tolerated in #gout. ##Rapamycin nanoparticle Rx w SEL 212 a uricase -infusion reactions 3.4% - all premeds w steroids and antihistamines- some stomatitis - seemed to lower uric acid and have good tolerability LB0002 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Jul 05, 2023

RT @drdavidliew : Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3 LB0003 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Jul 05, 2023

RT @Janetbirdope :What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more resolved symptoms. RA developed in both groups ACPA+ develop more rapidly -if resolution, still more MRI + vs neg. #EULAR2023 POS319. Diff patterns of progression

Dr. John Cush RheumNow ( View Tweet)

Jul 05, 2023

RT @Janetbirdope : I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324. Small differences but maybe a script to go south is the right Rx!

Dr. John Cush RheumNow ( View Tweet)

Jul 05, 2023

×